HLS Therapeutics Plans to Buyback Up to 5% of Its Shares
By Robb M. Stewart HLS Therapeutics plans to buy back up to 5% of its issued and outstanding shares over the next year. The pharmaceutical company said...
Robbm Stewart Toronto Stock Exchange Article Normal Healthcare Life Sciences Corporate Strategy Planning Corporate Funding
Source: marketwatch.com